Our Roadmap
Join us on a mission to transform early disease detection. TOBY is building a platform designed to detect multiple conditions early, using a single, simple urine sample. While our long-term vision is to expand across various disease conditions, we recognize that groundbreaking change starts with focused, decisive steps.
Explore our development journey and see how we’re shaping the future of early detection.
Performance
AUC, or “Area Under the Curve,” is one of the most important ways to evaluate how well a diagnostic model performs. It measures how accurately a test can distinguish between positive and negative cases, such as cancer and no cancer.
AUC values range from 0.5 to 1.0:
- AUC = 0.5 means the test performs no better than random chance
- AUC = 1.0 means the test is perfect
Diagnostic tests are typically rated as follows:
- Below 0.8 is considered poor performance
- Above 0.8 is a strong test
- Above 0.9 is excellent
Improving performance becomes more difficult at the high end of the scale, but the payoff is critical. That is why TOBY is being built to meet the highest bar. Our goal is to consistently deliver AUCs above 0.9, ensuring excellent performance in early cancer detection.
Leading the Way in Early Cancer Detection
TOBY Oncology
Breast Cancer
Global Cancer Incidence: 12.5%
Our Test AUC: Excellent
Mamogram Test: AUC = 0.78
Lung Cancer
Global Cancer Incidence: 12.2%
Our Test AUC: Excellent
LDCT Scan Test: AUC = 0.85
Colorectal Cancer
Global Cancer Incidence: 10.7%
Our Test AUC: Excellent
FIT Test: AUC = 0.92
Prostate Cancer
Global Cancer Incidence: 7.8%
Our Test AUC = Excellent
PSA Test: AUC = 0.68
Stomach Cancer
Global Cancer Incidence: 6.0%
Our Test AUC: Excellent
Competitor Test: None
Bladder Cancer
Global Cancer Incidence: 3.2%
Our Test AUC = Excellent
Competitor Test: None
Pancreatic Cancer
Global Cancer Incidence: 2.7%
Our Test AUC: Excellent
Competitor Test: None
Cervical Cancer
Global Cancer Incidence: 2.7%
Our Test AUC: Excellent
Competitor Test: None
Kidney Cancer
Global Cancer Incidence: 2.4%
Our Test AUC: Excellent
Competitor Test: None
Ovarian Cancer
Global Cancer Incidence: 1.7%
Our Test AUC: Excellent
Competitor Test: None
TOBY Oncology Leadership
Experienced Leadership in Cancer & Diagnostics
Proven operators in cancer, diagnostics and data
Matthew Collier
Chief Executive Officer
Serial CEO across 5 companies, tier-1 consulting global practice head, diagnostics depth
Dan Collins
Executive Chairman
Founder/CEO of Genesis Healthcare, Cancer and diagnostics depth
Clark Golestani
Board of Directors
Former President, Emerging Businesses & Global CIO at Merck, Advisor to New Mountain Capital and Advent